{"id":816738,"date":"2026-06-01T18:12:02","date_gmt":"2026-06-01T18:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=816738"},"modified":"2026-06-01T18:12:02","modified_gmt":"2026-06-01T18:12:02","slug":"epilepsy-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2036-delveinsight-es-therapeutics-phytotech-therapeutics-ucb-biopharma-sk-life-science","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/epilepsy-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2036-delveinsight-es-therapeutics-phytotech-therapeutics-ucb-biopharma-sk-life-science_816738.html","title":{"rendered":"Epilepsy Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 \u2013 DelveInsight | ES Therapeutics, PhytoTech Therapeutics,  UCB Biopharma, SK Life Science"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1780087931.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Epilepsy Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 &ndash; DelveInsight | ES Therapeutics, PhytoTech Therapeutics,  UCB Biopharma, SK Life Science\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1780087931.jpg\" alt=\"Epilepsy Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 &ndash; DelveInsight | ES Therapeutics, PhytoTech Therapeutics,  UCB Biopharma, SK Life Science\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Epilepsy Companies in the market include &#8211; Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma\/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals\/Knopp Biosciences, and others.<\/div>\n<p style=\"text-align: right;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Epilepsy Market Insights, Epidemiology, and Market Forecast-2036&Prime;<\/strong> report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Epilepsy Market Report <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/epilepsy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Epilepsy Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The epilepsy market size across the 7MM was valued at approximately <strong>USD 9 billion in 2023<\/strong> and is projected to expand at a <strong>CAGR of 7%<\/strong> during the forecast period from 2026 to 2036, supported by rising disease prevalence and ongoing advancements in therapeutic options.<\/p>\n<\/li>\n<li>\n<p><strong>In March 2026, Xenon Pharmaceuticals<\/strong> announced positive topline results from the Phase III (X-TOLE2) study of azetukalner in focal onset seizures (FOS). Xenon anticipates submitting a New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026. If approved, azetukalner would be the only KV7 potassium channel opener available for the treatment of epilepsy.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Biohaven Pharmaceuticals<\/strong> announced preliminary data from an ongoing open-label extension (OLE) study of opakalim, a selective Kv7 channel activator, in focal epilepsy, with pivotal results in the indication expected in 2026.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2025, Neurelis<\/strong> announced FDA approval of<strong> VALTOCO (diazepam nasal spray)<\/strong> for the short-term treatment of seizure clusters (acute repetitive seizures) in patients aged 2 years and older.<\/p>\n<\/li>\n<li>\n<p><strong>In September 2025, Actio Biosciences<\/strong> gave the first dose to a participant in the Phase Ia clinical trial of ABS-1230, a KCNT1 (potassium sodium-activated channel subfamily T member 1) inhibitor designed for epilepsy treatment. The trial is a double-blind, randomized, placebo-controlled study assessing single and multiple ascending doses and the impact of food in healthy volunteers. Conducted in Australia, the study will evaluate the pharmacokinetics, safety, and tolerability of ABS-1230.<\/p>\n<\/li>\n<li>\n<p><strong>In June 2025, Epiminder,<\/strong> a leader in implantable continuous EEG monitoring (iCEM&trade;), has announced the publication of findings from its pivotal UMPIRE (sUb-scalp Monitoring ePileptic seIzuREs) trial in Epilepsia. The study, carried out at major hospitals in Australia, confirmed the safety and effectiveness of iCEM&trade;, showing that the system can record high-quality EEG data over long durations, comparable to conventional scalp-based EEG monitoring.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2025, Rapport Therapeutics, Inc. (Nasdaq: RAPP),<\/strong> a clinical-stage biotech company focused on developing small molecule precision therapies for neurological and psychiatric conditions, announced its financial results for the first quarter ending March 31, 2025, along with a business update. The company described 2025 as a pivotal year, as it moves toward presenting initial proof-of-concept data for RAP-219 from its Phase 2a trial in patients with refractory focal epilepsy and advances its pipeline-in-a-product approach by launching a clinical trial for bipolar mania.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2025, In a Phase Ib\/IIa trial, Lundbeck&rsquo;s<\/strong> receptor superagonist, developed to treat seizures linked to developmental and epileptic encephalopathies (DEEs), demonstrated a 61.2% reduction in total seizures. Interim data from the open-label extension (OLE) of the Pacific trial (NCT05364021), which evaluated bexicaserin, an oral 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, in patients previously on placebo, revealed a 57.3% decrease in countable motor seizures and a 61.2% reduction in total seizures in those who had switched from placebo.<\/p>\n<\/li>\n<li>\n<p><strong>In March 2025, QurAlis Corporation,<\/strong> a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative and neurological diseases, announced positive topline results from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101. The study, conducted in healthy volunteers, assessed biomarkers associated with amyotrophic lateral sclerosis (ALS) and epilepsy.<\/p>\n<\/li>\n<li>\n<p>Several anti-epileptic drugs (AEDs) have received approval and are widely available as generics, including lamotrigine, sodium valproate, carbamazepine, levetiracetam, and topiramate. Newer approved therapies include Azetukalner (XCOPRI), Ganaxolone (ZTALMY), Perampanel (FYCOMPA), Diazepam (LIBERVANT), intranasal Midazolam (NAYZILAM), Cannabidiol (EPIDIOLEX), Brivaracetam (BRIVIACT), and Clobazam oral soluble film (SYMPAZAN).<\/p>\n<\/li>\n<li>\n<p>The epilepsy treatment landscape is evolving from symptomatic seizure control to mechanism-driven and precision therapies, particularly in drug-resistant and rare epileptic syndromes.<\/p>\n<\/li>\n<li>\n<p>Drug-resistant epilepsy (~30&ndash;40% of patients) remains a major unmet need, driving the development of novel agents targeting ion channels, synaptic transmission, and neuroinflammation.<\/p>\n<\/li>\n<li>\n<p>According to global epidemiological estimates, in 2025, the total number of individuals living with Epilepsy is ~50&ndash;70 million worldwide, making it one of the most common chronic neurological disorders globally.<\/p>\n<\/li>\n<li>\n<p>The US had the highest cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.<\/p>\n<\/li>\n<li>\n<p>Epidemiological studies indicate that the prevalence of epilepsy in the general population is approximately ~0.5&ndash;1.0% (5&ndash;10 per 1,000 individuals), with a higher burden observed in low- and middle-income countries due to increased risk factors and limited access to care.<\/p>\n<\/li>\n<li>\n<p>Focal epilepsy accounts for ~67% of all cases, while generalized epilepsy represents ~20&ndash;30%, with the remaining cases classified as unknown or combined onset types.<\/p>\n<\/li>\n<li>\n<p>Secondary epidemiological analyses highlight that incidence follows a bimodal age distribution, with peaks in early childhood and adults over 60 years, largely driven by genetic causes in pediatric patients and cerebrovascular disease in older adults.<\/p>\n<\/li>\n<li>\n<p>The prevalence of epilepsy is reported to be slightly higher in males than females in several population-based studies, although gender differences are generally modest and vary by region and underlying etiology.<\/p>\n<\/li>\n<li>\n<p><strong>Key Epilepsy Companies:<\/strong> Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma\/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals\/Knopp Biosciences, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Epilepsy Therapies:<\/strong> LIBERVANT (diazepam buccal film), EPIDIOLEX\/EPIDYOLEX (cannabidiol), XCOPRI\/ONTOZRY (cenobamate), AFINITOR DISPERZ\/VOTUBIA (everolimus), XEN1101\/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others<\/p>\n<\/li>\n<li>\n<p>The Epilepsy market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Seizures can vary in severity and may involve changes in behavior, consciousness, muscle control, or sensory perception. The condition can develop at any age and may result from various factors, including genetics, brain injury, infections, or structural brain abnormalities. Epilepsy is typically managed with medication, lifestyle adjustments, and sometimes surgery for more severe cases.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The Epilepsy epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Epilepsy market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalent Population of Epilepsy<\/p>\n<\/li>\n<li>\n<p>Total Diagnosed Prevalent Population of Epilepsy<\/p>\n<\/li>\n<li>\n<p>Gender-specific Diagnosed Prevalence of Epilepsy<\/p>\n<\/li>\n<li>\n<p>Diagnosed Prevalence of Epilepsy Based on Seizure Types in Adults<\/p>\n<\/li>\n<li>\n<p>Diagnosed Prevalence of Epilepsy Based on Seizure Types in Children<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Epilepsy epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Diazepam (VALTOCO):<\/strong> Neurelis\/Aculys Pharma<\/p>\n<\/li>\n<li>\n<p><strong>Cannabidiol (EPIDIOLEX):<\/strong> Greenwich Biosciences\/Jazz Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>Cenobamate (XCOPRI):<\/strong> SK Biopharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>LIBERVANT (diazepam buccal film):<\/strong> Aquestive Therapeutics\/Atnahs Pharma (Pharmanovia)<\/p>\n<\/li>\n<li>\n<p><strong>EPIDIOLEX\/EPIDYOLEX (cannabidiol):<\/strong> Jazz Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>XCOPRI\/ONTOZRY (cenobamate):<\/strong> SK Biopharmaceutical\/Angelini Pharma\/Ono Pharmaceutical<\/p>\n<\/li>\n<li>\n<p><strong>AFINITOR DISPERZ\/VOTUBIA (everolimus):<\/strong> Novartis<\/p>\n<\/li>\n<li>\n<p><strong>XEN1101\/Azetukalner:<\/strong> Xenon Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>Soticlestat (TAK-935):<\/strong> Takeda\/Ovid Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>BHV-7000 (KB-3061):<\/strong> Biohaven Pharmaceuticals\/Knopp Biosciences<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Epilepsy market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Rising Prevalence of Epilepsy: The increasing global burden of epilepsy and seizure-related disorders is significantly driving demand for effective treatment options.<\/p>\n<\/li>\n<li>\n<p>Advancements in Anti-Epileptic Therapies: Continuous development of novel anti-epileptic drugs (AEDs), targeted therapies, and improved drug formulations is supporting market growth.<\/p>\n<\/li>\n<li>\n<p>Growing Awareness and Early Diagnosis: Increasing awareness campaigns, improved neurological screening, and better access to healthcare services are leading to earlier diagnosis and treatment initiation.<\/p>\n<\/li>\n<li>\n<p>Strong Pipeline and Research Activities: Ongoing clinical trials and increased investments in neuroscience research are accelerating the development of innovative epilepsy therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Availability of Generic Drugs: The widespread availability of low-cost generic anti-epileptic drugs creates pricing pressure for branded therapies.<\/p>\n<\/li>\n<li>\n<p>Drug Resistance in Patients: A significant proportion of epilepsy patients experience drug-resistant seizures, limiting the effectiveness of existing therapies.<\/p>\n<\/li>\n<li>\n<p>Side Effects Associated with AEDs: Long-term use of anti-epileptic medications may lead to adverse effects such as dizziness, fatigue, cognitive impairment, and mood disorders, impacting patient adherence.<\/p>\n<\/li>\n<li>\n<p>High Cost of Advanced Therapies: Innovative biologics, surgical procedures, and neurostimulation devices can be expensive, restricting accessibility in low- and middle-income regions.<\/p>\n<\/li>\n<li>\n<p>Limited Access to Specialized Care: Inadequate availability of neurologists, epilepsy centers, and diagnostic infrastructure in certain regions may hinder timely treatment.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Epilepsy Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2022&ndash;2036<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Epilepsy Companies:<\/strong> Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma\/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals\/Knopp Biosciences, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Epilepsy Therapies:<\/strong> LIBERVANT (diazepam buccal film), EPIDIOLEX\/EPIDYOLEX (cannabidiol), XCOPRI\/ONTOZRY (cenobamate), AFINITOR DISPERZ\/VOTUBIA (everolimus), XEN1101\/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others<\/p>\n<\/li>\n<li>\n<p><strong>Epilepsy Therapeutic Assessment:<\/strong> Epilepsy current marketed and Epilepsy emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Epilepsy Market Dynamics:<\/strong> Epilepsy market drivers and Epilepsy market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Epilepsy Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Epilepsy Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Epilepsy companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Epilepsy Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Epilepsy<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Epilepsy<\/p>\n<p style=\"text-align: justify;\">4. Epilepsy Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Epilepsy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Epilepsy Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Epilepsy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Epilepsy<\/p>\n<p style=\"text-align: justify;\">9. Epilepsy Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Epilepsy Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Epilepsy Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Epilepsy Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Epilepsy Market Analysis (2022&ndash;2036)<\/p>\n<p style=\"text-align: justify;\">14. Epilepsy Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Epilepsy Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Epilepsy Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Epilepsy Appendix<\/p>\n<p style=\"text-align: justify;\">18. Epilepsy Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=epilepsy-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2036-delveinsight-es-therapeutics-phytotech-therapeutics-ucb-biopharma-sk-life-science\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> https:\/\/www.delveinsight.com\/<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=epilepsy-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2036-delveinsight-es-therapeutics-phytotech-therapeutics-ucb-biopharma-sk-life-science\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Epilepsy Companies in the market include &#8211; Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma\/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals\/Knopp Biosciences, and others. &nbsp; DelveInsight&rsquo;s &ldquo;Epilepsy Market Insights, Epidemiology, and Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/epilepsy-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2036-delveinsight-es-therapeutics-phytotech-therapeutics-ucb-biopharma-sk-life-science_816738.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-816738","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=816738"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816738\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=816738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=816738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=816738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}